Literature DB >> 21461898

The impact of mixing surgical subspecialty patients on wound infection rates.

Mohiemen Anwar1, Louisa Ferguson, Zaid Awad, Khalid Ghufoor.   

Abstract

To investigate the impact of mixing surgical subspecialty patients on post-operative wound infections. A retrospective analysis of post-operative wound infections in head and neck surgery patients before and after mixing them with urology patients. We selected two periods that are identical in duration and seasonal spread. The first was from March 2005 to November 2005 and the second was from March 2006 to November 2006. 1,381 patients underwent head and neck surgery at our institution in the two periods; 705 in the first and 676 in the second. Excluding MRSA positive swabs, the rate of positive swabs or "episodes" was 4% in the first group (2005) and 10% in the second group (2006). The monthly breakdown showed a significant increase in the second group (2006) (p = 0.024). Uro-genital microorganisms were the main factor contributing to the increase in wound infection rates in the second period (p = 0.008). Other organisms like MRSA, remained statistically unchanged (p = 0.464). It is recommend that head and neck surgery patients are better managed on separate wards. Clinicians should have a low threshold of suspecting a broader range of microorganisms when other specialty patients are on the same ward.

Entities:  

Mesh:

Year:  2011        PMID: 21461898     DOI: 10.1007/s00405-011-1578-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  8 in total

1.  Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee.

Authors:  A J Mangram; T C Horan; M L Pearson; L C Silver; W R Jarvis
Journal:  Infect Control Hosp Epidemiol       Date:  1999-04       Impact factor: 3.254

2.  Risk factors for surgical-site infections in head and neck cancer surgery.

Authors:  Carlos Jorge Lotfi; Rita de Cássia Cavalcanti; Adriana Maria Costa e Silva; Maria do Rosário Dias de Oliveira Latorre; Karina de Cássia Braga Ribeiro; André Lopes Carvalho; Luiz Paulo Kowalski
Journal:  Otolaryngol Head Neck Surg       Date:  2008-01       Impact factor: 3.497

3.  Surgical site infection: incidence and impact on hospital utilization and treatment costs.

Authors:  Gregory de Lissovoy; Kathy Fraeman; Valerie Hutchins; Denise Murphy; David Song; Brian B Vaughn
Journal:  Am J Infect Control       Date:  2009-04-23       Impact factor: 2.918

4.  Adverse impact of surgical site infections in English hospitals.

Authors:  R Coello; A Charlett; J Wilson; V Ward; A Pearson; P Borriello
Journal:  J Hosp Infect       Date:  2005-06       Impact factor: 3.926

5.  Reducing methicillin-resistant Staphylococcus aureus (MRSA) patient exposure by infection control measures.

Authors:  P Johnston; A R Norrish; T Brammar; N Walton; T A Hegarty; N P Coleman
Journal:  Ann R Coll Surg Engl       Date:  2005-03       Impact factor: 1.891

6.  Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.

Authors:  Gulay Yetkin; Baris Otlu; Aysegul Cicek; Cigdem Kuzucu; Riza Durmaz
Journal:  Am J Infect Control       Date:  2006-05       Impact factor: 2.918

Review 7.  The use of prophylactic antibiotics in head and neck oncological surgery.

Authors:  Ricard Simo; Gary French
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2006-04       Impact factor: 2.064

8.  Provisional guidelines for applying the Department of Health (England) 18-week-patient pathway to specialist rheumatology care.

Authors:  D A Walsh; C Kelly; A Bosworth; C Price; G Burbage
Journal:  Rheumatology (Oxford)       Date:  2007-05-10       Impact factor: 7.580

  8 in total
  1 in total

1.  Plastic surgeons' self-reported operative infection rates at a Canadian academic hospital.

Authors:  Wendy Ky Ng; Manraj Nirmal Kaur; Achilleas Thoma
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.